Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-3014 in Tenosynovial Giant Cell Tumor
NCT07832747Phase 2Not yet recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vimseltinib in tenosynovial giant cell tumor (TGCT), sponsored by Ono Pharmaceutical. Primary endpoint: Objective Response Rate at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
vimseltinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT07832747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832747.